Trding - a lot of information here...thank you ...
Post# of 148190
Base only on severe side effects of Maraviroc :
Liver toxicity , cardiac events,including heart attacks , and many more ,
when Leronlimab will be approved , I really don't see many physicians using Maraviroc with patients , HIV or cancers , IMO , maybe physicians less informed ....
And Leronlimab inhibits CCR5 without blocking natural activity of CCR5 ,
one of the reason for no serious side effects .
And no resistance so far....
And no interaction with other drugs so far...
And it is working on drug resistant patients so far...
And efficacy in combo with 350 mg is 81% , compare with 45% with Maraviroc , and 43% with Ibalizumab ...
And this is only medicine working as mono in HIV , with efficacy about 90% so far .....
The more I read the more I understand why Dr Pestell after DD Leronlimab. left BP and Maraviroc ...
I am hoping that this week news will come about injections of some TNBC patients .